Safety Study of XT-150 in Participants With ALS

This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS). Participants providing informed consent and meeting all study eligibility criteria will be enrolled in the study and will receive a single injection of XT-150 at the Baseline visit. Follow-up visits will occur over 180 days (6 months) after the injection. 8 participants (4 participants per dose level) will be enrolled sequentially in up to 2 ascending, single dose cohorts: Cohort 1: 1.5 mg XT-150 Cohort 2: 4.5 mg XT-150

The main questions this study is aiming to answer are: * What adverse events are reported during this study? An adverse event is any "side effect" that participants have during a study. Adverse events may or may not be caused by XT-150. The study doctors will check participants' ALS and general health throughout the trial. * Does XT-150 have any effects on participants' physical examination findings, vital signs, or laboratory values? In addition to evaluating the safety of XT-150, this study will also collect samples to provide information on the following: * The levels of XT-150 in your body * The effect of XT-150 on cytokines including interleukin (IL)-10 * The effect of XT-150 on relevant ALS biomarkers such as Neurofilament Light (NfL) In addition, ALS functional score, breathing capacity and strength will be collected over the course of the study.